WO2012102625A3 - Therapeutic composition - Google Patents

Therapeutic composition Download PDF

Info

Publication number
WO2012102625A3
WO2012102625A3 PCT/NZ2012/000005 NZ2012000005W WO2012102625A3 WO 2012102625 A3 WO2012102625 A3 WO 2012102625A3 NZ 2012000005 W NZ2012000005 W NZ 2012000005W WO 2012102625 A3 WO2012102625 A3 WO 2012102625A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic composition
glyargargalaalaproglyargaibglygly
seq
sequence
composition
Prior art date
Application number
PCT/NZ2012/000005
Other languages
French (fr)
Other versions
WO2012102625A2 (en
Inventor
Frank Sieg
Original Assignee
Curonz Holdings Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curonz Holdings Company Limited filed Critical Curonz Holdings Company Limited
Publication of WO2012102625A2 publication Critical patent/WO2012102625A2/en
Publication of WO2012102625A3 publication Critical patent/WO2012102625A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a composition comprising ophthalmologically acceptable excipients and an effective amount of a peptide comprising the sequence: GlyArgArgAlaAlaProGlyArgAibGlyGly (SEQ ID NO:1)or the sequence GlyArgArgAlaAlaProGlyArgAibGlyGly-NH2 (SEQ ID NO: 2) and methods of use thereof.
PCT/NZ2012/000005 2011-01-28 2012-01-27 Therapeutic composition WO2012102625A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ590769 2011-01-28
NZ59076911 2011-01-28

Publications (2)

Publication Number Publication Date
WO2012102625A2 WO2012102625A2 (en) 2012-08-02
WO2012102625A3 true WO2012102625A3 (en) 2012-11-01

Family

ID=46581323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2012/000005 WO2012102625A2 (en) 2011-01-28 2012-01-27 Therapeutic composition

Country Status (1)

Country Link
WO (1) WO2012102625A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877195B1 (en) * 2012-07-27 2018-03-21 Curonz Holdings Company Limited Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury
US20160031937A1 (en) * 2013-03-08 2016-02-04 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919813A (en) * 1998-03-13 1999-07-06 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US20050131212A1 (en) * 2001-08-24 2005-06-16 Neuren Pharmaceuticals Ltd. Neural regeneration peptides and methods for their use in treatment of brain damage
WO2009051844A1 (en) * 2007-10-17 2009-04-23 Neuren Pharmaceuticals Limited Synthetic analogues of neural regeneration peptides
US20090148886A1 (en) * 2007-12-07 2009-06-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of identifying compounds that decrease intraocular pressure

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919813A (en) * 1998-03-13 1999-07-06 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US5919813C1 (en) * 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US20050131212A1 (en) * 2001-08-24 2005-06-16 Neuren Pharmaceuticals Ltd. Neural regeneration peptides and methods for their use in treatment of brain damage
WO2009051844A1 (en) * 2007-10-17 2009-04-23 Neuren Pharmaceuticals Limited Synthetic analogues of neural regeneration peptides
US20090148886A1 (en) * 2007-12-07 2009-06-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of identifying compounds that decrease intraocular pressure

Also Published As

Publication number Publication date
WO2012102625A2 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2009094172A3 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2012009748A (en) Use of transforming growth factor - beta 1 (tgf-î²1) inhibitor peptides for the treatment of corneal fibrosis and/or haze.
WO2009012176A3 (en) Methods and compositions for treating brain diseases
MY172292A (en) Vectors and sequences for the treatment of diseases
NZ611108A (en) Methods of treating fgf21-associated disorders
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
UA118167C2 (en) Peptides and their use
MX2013004190A (en) Compositions and methods of treating pulmonary hypertension.
WO2013000922A9 (en) Ccr2 antagonist peptides
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
SI2739615T1 (en) Phenyl-3-aza-bicyclo(3.1.0)hex-3-yl-methanones and the use thereof as medicament
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
IN2015DN00585A (en)
JP2010265269A5 (en)
WO2011123858A3 (en) Ccn3 peptides and analogs thereof for therapeutic use
IN2014DN09367A (en)
WO2015009820A3 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2013074871A3 (en) Humanin analogs
WO2013021284A3 (en) Anti-il-6 vaccine composition
EP2729157A4 (en) Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739897

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12739897

Country of ref document: EP

Kind code of ref document: A2